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Abstract
© 2016,  Springer  Science+Business  Media  New  York.Due  to  lack  of  effective  therapies,
muscular dystrophies became a focus for gene therapy. Multiple pre-clinical studies have shown
successful restoration of dystrofin and dysferlin by RNA editing both in vivo and in vitro, but
possibility of a clinical translation is still obscure. A number of new chemicals are being studied,
and a search for new techniques is ongoing. This work is intended to give a brief overview of the
current state of the RNA editing for treating muscular dystrophies.
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